Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects

BACKGROUND: Several concerns exist on the immunogenicity of SARS-CoV-2 vaccines in multiple sclerosis (MS) subjects due to their immunomodulating disease modifying therapies (DMTs). Here we report a comparison of the humoral response to BNT162b2-mRNA coronavirus (COVID)-19 vaccine and the immunologi...

Descripción completa

Detalles Bibliográficos
Autores principales: Maniscalco, Giorgia Teresa, Manzo, Valentino, Ferrara, Anne Lise, Perrella, Alessandro, Di Battista, Mariaelena, Salvatore, Simona, Graziano, Daniela, Viola, Assunta, Amato, Gerardino, Moreggia, Ornella, Di Giulio Cesare, Daniele, Barbato, Stefano, Servillo, Giovanna, Longo, Katia, Di Giovanni, Mario, Scarpati, Barbara, Muggianu, Simona Maria, Longo, Giuseppe, Russo, Giuseppe, Andreone, Vincenzo, De Rosa, Veronica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683261/
https://www.ncbi.nlm.nih.gov/pubmed/34929455
http://dx.doi.org/10.1016/j.msard.2021.103455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683261/
https://www.ncbi.nlm.nih.gov/pubmed/34929455
http://dx.doi.org/10.1016/j.msard.2021.103455

Ejemplares similares